Therapies based on non-nucleoside reverse transcriptase inhibitors would mediate this effect through the promotion of apoptosis
A Spanish study published in the Journal of Antimicrobial Chemotherapy has concluded that people with HIV who managed to be cured of hepatitis C virus (HCV) infection experienced a greater recovery from liver fibrosis if their antiretroviral treatment contained an inhibitor of the Non-nucleoside analog reverse transcriptase (NNRTI).
The high cure rates of hepatitis C with direct-acting antivirals (DAAs) have made it possible to observe how the organ reacts - which has spent years or even decades under the action of HCV - after the cure in a large number of people. Several studies have shown that the degree of reversibility of liver fibrosis is greater the less advanced it was before obtaining a cure. However, little is known about the influence of antiretroviral treatment on the degree of liver recovery of people with HIV after being cured of hepatitis C.